TY  - JOUR
AU  - Olmedo-Martin, Raul Vicente
AU  - Amo-Trillo, Victor
AU  - Gonzalez-Grande, Rocio
AU  - Jimenez-Perez, Miguel
PY  - 2017
DO  - 10.17235/reed.2017.5024/2017
SN  - 1130-0108
UR  - http://hdl.handle.net/10668/11424
T2  - Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
AB  - Vedolizumab is a humanized IgG1 monoclonal antibody that selectively blocks the lymphocyte integrin α4β7 and prevents its interaction with endothelial adhesion molecules and subsequent transmigration to the gastrointestinal tract. The drug was...
LA  - en
PB  - Sociedad Española de Patología Digestiva
KW  - Vedolizumab
KW  - Liver transplant
KW  - Ulcerative colitis
KW  - Adult
KW  - Antibodies, Monoclonal, Humanized
KW  - Cholangitis, Sclerosing
KW  - Colitis, Ulcerative
KW  - Female
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Liver Transplantation
KW  - Treatment Outcome
TI  - Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.
TY  - research article
VL  - 109
ER  -